TEE
AVXL icon

Tibra Equities Europe’s Anavex Life Sciences AVXL Stock Holding History

Tibra Equities Europe’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-84,445
Closed -$258K – 259
2019
Q1 		$258K Buy
+84,445
New +$202K 0.03% 349

Other funds holding AVXL

PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Tibra Equities Europe's AVXL Position: Q2 2019 in Review

Tibra Equities Europe sold out of Anavex Life Sciences (AVXL) in Q2 2019, closing a stake of 84,445 shares — an estimated $258K sold.

Tibra Equities Europe first reported a position in AVXL in Q1 2019 and held it in 1 quarter. The position peaked at $258K in Q1 2019. 59 funds tracked by Wall St. Rank hold AVXL as of Q2 2019.

  • Tibra Equities Europe reported no remaining Anavex Life Sciences position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 84,445 Anavex Life Sciences shares in Q2 2019, an estimated $258K.
  • Tibra Equities Europe first reported a position in Anavex Life Sciences in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Anavex Life Sciences position peaked at $258K in Q1 2019.
  • 59 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.